共 50 条
- [31] A phase Ib study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumors.CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9060S - 9060SKitzen, JAttard, Gde Jonge, MReid, AVerweij, JPronk, LZhi, JGFong, PZugmaier, GDe Bono, J
- [32] Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Keilholz, U.Moiseyenko, V.Makhson, A.Semiglazov, V.Learoyd, M.Saunders, A.Stuart, M.Tjulandin, S.
- [33] A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumorsEUROPEAN JOURNAL OF CANCER, 2016, 69 : S21 - S22Razak, A.Gore, L.Britten, C. D.Miller, W. H.Uy, G. L.Nichols, G.Middleton, S.Blotner, S.Zhi, J.Jukofsky, L.Pierceall, W.Higgins, B.Chen, L. C.
- [34] Clinical pharmacokinetics (PK) and translational PK-pharmacodynamic (PD) modeling and simulation to predict antitumor response of various dosing schedules to guide the selection of a recommended phase II dose (RP2D) and schedule for the investigational agent MLN0128.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Patel, Chirag G.Patel, MayankChakravarty, ArijitGangolli, Esha A.Barry, EllyWestin, Eric H.Jessen, KattiChitnis, Shripad D.Infante, Jeffrey R.Gordon, Michael S.Macarulla, TeresaCervantes-Ruiperez, AndresJalal, Shadia IbrahimVenkatakrishnan, Karthik
- [35] A PHASE-I dose escalation study of cyclical weekly temozolomide(TMZ)combined with weekly pegylated interferon alfa-2b(PEG-IFN) in patients(PTS)with refractory and/or advanced solid tumors.CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S52 - S52Dandamudi, U. B.Beelen, A. P.Reddy, N. J.Crosby, N. C.Emstoff, M. S.Lewis, L. D.
- [36] A phase 1b study of pertuzumab (P), a recombinant humanized antibody to HER2, and docetaxel (D) in patients (pts) with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 232S - 232SAttard, GKitzen, JJde Bono, JVerweij, JPronk, LZhi, JBlagden, SPReade, SEZugmaier, Gde Jonge, MJ
- [37] A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2013, 71 : 523 - 530Luis E. RaezKyriakos PapadopoulosAlejandro D. RicartE. Gabriella ChioreanRobert S. DiPaolaMark N. SteinCaio M. Rocha LimaJames J. SchlesselmanKhaled TolbaVirginia K. LangmuirStewart KrollDonald T. JungMetin KurtogluJoseph RosenblattTheodore J. Lampidis
- [38] A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumorsCANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 523 - 530Raez, Luis E.Papadopoulos, KyriakosRicart, Alejandro D.Chiorean, E. GabriellaDiPaola, Robert S.Stein, Mark N.Lima, Caio M. RochaSchlesselman, James J.Tolba, KhaledLangmuir, Virginia K.Kroll, StewartJung, Donald T.Kurtoglu, MetinRosenblatt, JosephLampidis, Theodore J.
- [39] RECOMMENDED PHASE 2 DOSE, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY EFFICACY OF THE IL-15 SUPERAGONIST SO-C101 AS MONOTHERAPY IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A534 - A534Marabelle, AurelienChampiat, StephaneGalvao, VladimirNaing, AungJanku, FilipLoRusso, PatriciaGrell, PeterSachse, RichardBechard, DavidKiemle-Kallee, JoachimGarralda, Ellena
- [40] Joint modeling of safety and peripheral mode-of-action (MoA) biomarkers to support RP2D identification in Phase 1 study of SAR444245 (SAR'245) as monotherapy (mono) or combined with pembrolizumab (pembro) in patients with advanced solid tumorsCANCER RESEARCH, 2023, 83 (07)Fu, SiqingFalchook, Gerald S.Barve, MinalMcKean, MeredithTan, Tira J.Lemech, CharlotteChee, Cheng E.Marina, NeyssaAbbadessa, GiovanniMeng, RobinRotolo, FedericoWang, HongDeng, JasonWang, WentingWang, RuiMeniawy, Tarek